HUTCHMED (China) signs exclusive licensing deal with GSK for investigational cancer drug
03/09/2026 05:22
HUTCHMED (China) signs exclusive licensing deal with GSK for investigational cancer drug Sept 3 (Reuters) - HUTCHMED (China) 0013.HK said on Thursday its unit had signed an exclusive development and licensing agreement with a subsidiary of GSK GSK.L to develop and commercialise its investigational cancer drug, HMPL-A830.
The agreement grants the British drug maker's unit worldwide rights to develop and commercialise the drug outside Mainland China, Hong Kong, Macau and Taiwan.
(Reporting by Jasmeen Ara Shaikh in Bengaluru; Editing by Subhranshu Sahu)
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation